Adults diagnosed with muscle-invasive bladder cancer gained a new treatment option on July 10, 2026, when the FDA cleared the combination of pembrolizumab and enfortumab vedotin for use both before ...

Many think the next standard cancer treatment will pair two innovations.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Phase 3 KEYNOTE‑C93 trial evaluating KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, met its primary ...

Merck (MRK) stock is in focus as the company posts a late-stage trial win for anti-PD-1 therapy, Keytruda, in endometrial cancer. Read more here.

Keytruda, an immunotherapy agent, demonstrated significant improvement in both distant metastasis-free survival and recurrence-free survival compared to placebo. Keytruda (pembrolizumab) in the ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

Merck & Co.’s almighty Keytruda has become the first PD-1 inhibitor to show a benefit as a single agent for the front-line treatment of a subtype of endometrial cancer. | Merck & Co.’s almighty ...

Keytruda shows consistent efficacy and safety in advanced bladder carcinoma patients ineligible for platinum-based chemotherapy, with varying objective response rates and survival metrics across ...

Trillion Won Keytruda Biosimilar Race Heats Up Samsung Bioepis and global rivals race for market entry as MSDs 2029 patent ...